Skip to content

Effect of glycyrrhizic acid on the pharmacokinetics of talinolol

Effect of glycyrrhizic acid on the pharmacokinetics of talinolol

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-RRC-10000999
Enrollment
Unknown
Registered
2010-08-30
Start date
2009-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy male

Interventions

Group B:Give placebo for 6 d, tid, 3 tablets once
give talinolol 1 tablet in the seventh day
Group A:Give compound glycyrrhizin for 6 d, tid, 3 tablets once

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 24 Years

Inclusion criteria

Inclusion criteria: 1. Each subject was ascertained to be in good health as assessed by a medical history, physical examination, routine laboratory testing (which included hematologic, serum chemical, and urine testing), and a standard 12-lead electrocardiogram; 2. Only subjects with normal PR interval, resting pulse rate more than 55 beats/min, and a systolic/ diastolic blood pressure of more than 105/60mm Hg were recruited.

Exclusion criteria

Exclusion criteria: 1. Subject had significant illnesses within the preceding 28 days; 2. Routinely used medications; 3. History of cardiac, renal, hepatic, or gastrointestinal disease or of drug or alcohol abuse.

Design outcomes

Primary

MeasureTime frame
Serum concentration of talinolol;

Countries

China

Contacts

Public ContactHuan-De Li
lihuande1953@126.com+86 731 84436720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026